Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.37 |
| ▸ | MAOB | P27338 | 6/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | AOC2 | O75106 | 5/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542323 | 0.78 | MAOA (0.45) | MAOAMAOBPLAUAOC2DAO | |
| SCHEMBL5572317 | 0.77 | MAOA (0.38) | MAOAMAOBAOC2DAOIDO1 | |
| SCHEMBL11381215 | 0.75 | MAOA (0.37) | MAOAMAOBAOC2 | |
| SCHEMBL2449240 | 0.75 | MAOA (0.37) | MAOAMAOBAOC2DAONISCH | |
| SCHEMBL10654103 | 0.75 | MAOB (0.39) | MAOAMAOBAOC2DAONISCH | |
| SCHEMBL449445 | 0.75 | MAOA (0.37) | MAOAMAOBAOC2DAONISCH | |
| SCHEMBL502587 | 0.75 | MAOA (0.40) | MAOAMAOBAOC2DAOHTR2A | |
| SCHEMBL5215909 | 0.73 | HPGD (0.45) | MAOAMAOBAOC2DAONISCH | |
| SCHEMBL11140638 | 0.72 | TSHR (0.43) | MAOAMAOB | |
| SCHEMBL7477080 | 0.72 | CA2 (0.40) | MAOAMAOBAOC2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031705-A1 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS | OCULARIS PHARMA LLC (US) | 2015-01-29 | — | — | US | claimed |
| EP-1755591-A4 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS | OCULARIS PHARMA INC (US) | 2007-11-07 | — | — | EP | claimed |
| EP-1755591-A2 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS | Ocularis Pharma, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005123093-A2 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS | OCULARIS PHARMA, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050080056-A1 | Alpha 1 antagonist; reduces pupil size in dim light, but less reduction in pupil size in bright light; artificial tear; tamsulosin, urapidil | Ocuphire Pharma, Inc. | 2005-04-14 | — | — | US | claimed |
| CN-116710783-A | Detection of target analytes by cross-spray ESI mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116323568-A | Detection of target analytes by nanoESI mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-106167483-B | It can be used for compound, composition and the method for cholesterol mobilization | 塞伦尼斯医疗控股有限公司 | 2019-02-15 | — | — | CN | disclosed |
| CN-107011359-A | Compound, composition and the method mobilized available for cholesterol | 塞伦尼斯医疗控股有限公司 | 2017-08-04 | — | — | CN | disclosed |
| CN-103442714-B | Compounds, compositions and methods useful for cholesterol mobilization | 塞伦尼斯医疗控股有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-106167483-A | Can be used for compound, compositions and method that cholesterol is mobilized | 塞伦尼斯医疗控股有限公司 | 2016-11-30 | — | — | CN | disclosed |
| US-20150031705-A1 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS | OCULARIS PHARMA LLC (US) | 2015-01-29 | — | — | US | disclosed |
| US-6001517-A | A THERMOSETTING POLYMER WHICH CAN BE CURED THROUGH CYCLODEHYDRATION UPON HEATING AND A CURE ACCELERATOR WHICH CAN BE DEACTIVATED OF ITS CURE ACCELERATION PROPERTY BY IRRIDIATION OF LIGHT | KABUSHIKI KAISHA TOSHIBA (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5578697-A | DIELECTRIC POLYMERS FOR ELECTRONICS | KABUSHIKI KAISHA TOSHIBA (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0429535-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0429535-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-06-05 | — | — | EP | disclosed |
| EP-0359400-A1 | Fungicidal benzodioxane amine derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0359400-A1 | Fungicidal benzodioxane amine derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-21 | — | — | EP | disclosed |
| WO-1990002122-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| WO-1990002122-A1 | FUNGICIDAL BENZODIOXANE AMINE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031705-A1 | OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS | ADRA1D, ADRA1A, ADRA1B | MAOA 657/4885MAOB 1017/4885PLAU 3116/4885 |
| US-20050080056-A1 | Alpha 1 antagonist; reduces pupil size in dim light, but less reduction in pupil size in bright light; artificial tear; tamsulosin, urapidil | ADRA1A, ADRA1D, ADRA2A | MAOA 263/4885MAOB 890/4885PLAU 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.